Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.20M | -69.01M | -62.53M | -11.18M | -36.72M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.67M | 11.39M | 20.22M | -31.87M | -805.00K |
| Change in Net Operating Assets | -9.01M | 244.00K | -2.27M | 5.94M | -9.04M |
| Cash from Operations | -69.88M | -57.37M | -44.58M | -37.12M | -46.56M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -297.90M | 56.58M | -247.41M | 25.00M | 79.00M |
| Cash from Investing | -297.90M | 56.58M | -247.41M | 25.00M | 79.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 455.82M | 12.43M | 312.88M | 491.00K | 731.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -23.22M | -171.00K | -69.00K | -5.13M | 0.00 |
| Cash from Financing | 432.60M | 12.26M | 312.81M | -4.64M | 731.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 64.82M | 11.46M | 20.82M | -16.76M | 33.17M |